<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22328" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Glyburide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hardin</surname>
            <given-names>Maiah D.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jacobs</surname>
            <given-names>Tibb F.</given-names>
          </name>
          <aff>University of Louisiana Monroe</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maiah Hardin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tibb Jacobs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22328.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">According to the 2023 update of the American Diabetes Association Standards of Medical Care in Diabetes, glyburide and other sulfonylureas are considered viable options for adjunctive therapy, particularly for patients seeking potent agents with a higher chance of attaining glycemic targets. This comprehensive overview of glyburide focuses on its indications, mechanism of action, contraindications, adverse event profile, and monitoring considerations. This activity emphasizes the importance of glyburide as an effective therapeutic option in managing type 2 diabetes for interprofessional team members involved in patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with type 2 diabetes who may be appropriate candidates for glyburide therapy, considering factors such as glycemic control, renal function, and medication history.</p></list-item><list-item><p>Screen patients for contraindications and potential risks associated with glyburide, such as renal impairment or a history of hypoglycemia.</p></list-item><list-item><p>Assess the effectiveness of glyburide therapy in achieving glycemic control, monitoring blood glucose levels, and adjusting the treatment plan as needed.</p></list-item><list-item><p>Collaborate with other healthcare professionals, such as endocrinologists, pharmacists, and diabetes educators, to ensure comprehensive diabetes care and optimize the use of glyburide.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22328&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22328">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22328.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Glyburide, or glibenclamide, is a second-generation sulfonylurea approved by the Food and Drug Administration (FDA) for treating type 2 diabetes. The medication is available as a generic formulation. Glyburide is an adjunct therapy along with diet and exercise for managing diabetes.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref>&#x000a0;Treatment with glyburide has and continues to lower blood glucose levels successfully and is also available in combination&#x000a0;formulation with metformin. Typical doses for glyburide are relatively minute compared to first-generation sulfonylureas, and dosing is usually a once-daily morning dose.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>According to the American Diabetes Association (ADA) <italic toggle="yes">Standards of Medical Care in Diabetes</italic>&#x000a0;2023 update,&#x000a0;sulfonylureas such as glyburide are considered one of the multiple&#x000a0;options for adjunctive therapy, especially for patients seeking highly efficacious agents with a greater likelihood of achieving their glycemic goals.<xref ref-type="bibr" rid="article-22328.r2">[2]</xref> This recommendation focuses on patients with type 2 diabetes mellitus who do not have atherosclerotic cardiovascular disease or chronic kidney disease and have not achieved their HbA1C target despite exhausting first-line treatment options.<xref ref-type="bibr" rid="article-22328.r2">[2]</xref> However, recent updates in recommendations for first-line therapy emphasize the importance of tailoring treatment based on patient-specific factors, including comorbidities such as atherosclerotic cardiovascular disease, heart failure,&#x000a0;or chronic kidney disease, as well as individual management needs.<xref ref-type="bibr" rid="article-22328.r2">[2]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>For many years, glyburide has been studied off-label for treating neonatal syndromic hyperglycemia for patients with <italic toggle="yes">KCNJ11</italic> or <italic toggle="yes">ABCC8</italic> mutations&#x000a0;that encode subunits of the ATP-sensitive K<sup>+</sup>&#x000a0;(K<sub>ATP</sub>) channel gene.<xref ref-type="bibr" rid="article-22328.r3">[3]</xref>&#x000a0;Although no dose forms are available for children with these potassium channel defects, studies have included a newly-designed suspension with orphan drug status to evaluate its efficacy&#x000a0;against glyburide tablets.<xref ref-type="bibr" rid="article-22328.r4">[4]</xref>&#x000a0;Results from the research reflected significant decreases in HbA1C levels, further warranting&#x000a0;this off-label use.<xref ref-type="bibr" rid="article-22328.r4">[4]</xref></p>
        <p>Due to&#x000a0;glyburide's&#x000a0;sulfonylurea&#x000a0;receptor 1 (SUR1) receptor-blocking action, recent studies have shed light on the potential of&#x000a0;low doses of glyburide as a possible agent for reducing intracranial pressure and cerebral edema.<xref ref-type="bibr" rid="article-22328.r5">[5]</xref></p>
      </sec>
      <sec id="article-22328.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Glyburide, along with others in the&#x000a0;sulfonylurea class, exerts its mechanism of action based on increasing insulin secretion from beta cells in the pancreas.<xref ref-type="bibr" rid="article-22328.r6">[6]</xref>&#x000a0;Specifically, sulfonylureas bind to the SUR1 receptors in the membranes of the beta cells of potassium ATP-dependent channels.<xref ref-type="bibr" rid="article-22328.r6">[6]</xref><xref ref-type="bibr" rid="article-22328.r7">[7]</xref></p>
        <p>These agents block these channels, releasing insulin after the cell depolarizes.<xref ref-type="bibr" rid="article-22328.r8">[8]</xref>&#x000a0;At times, sulfonylureas bind to SUR2 receptors on cells in cardiac tissue and the endothelium.<xref ref-type="bibr" rid="article-22328.r7">[7]</xref>&#x000a0;</p>
        <p>After the initial insulin secretion, sulfonylureas can also decrease insulin clearance in the liver, increasing plasma insulin levels.<xref ref-type="bibr" rid="article-22328.r9">[9]</xref>&#x000a0;Glyburide, along with glipizide, is classified as a second-generation sulfonylurea due to its increased potency and difference in elimination, allowing their use in patients with renal and hepatic dysfunction.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Glyburide is metabolized in the liver via the CYP450 system; it is a CYP2C9 substrate. The drug has a half-life of 10 hours and is excreted in the bile (50%) and urine (50%).</p>
      </sec>
      <sec id="article-22328.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Glyburide is available in 1.25 mg, 2.5 mg, and 5 mg tablets.</p>
        <p><bold>Dosage&#x000a0;for type 2 diabetes:</bold>&#x000a0;1.25 mg to 20 mg orally, once or divided twice daily.</p>
        <p><bold>Formulation note:</bold> non-micronized and micronized glyburide formulations are not bioequivalent. Dosing must be re-titrated when switching between formulations.</p>
        <p>Glyburide is orally administered in typical initial dosages of 2.5 mg to 5 mg, with a maximum of 40 mg daily&#x02014;the maximum dosage is rarely used, as many&#x000a0;patients with type 2 diabetes do not require dosages higher than 10 mg per day.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref>&#x000a0;Clinical effects are also insignificant beyond dosages of 10 to 15 mg daily.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref><xref ref-type="bibr" rid="article-22328.r9">[9]</xref>&#x000a0;</p>
        <p>To optimize absorption and maximize the antidiabetic effect of sulfonylureas, including glyburide, it is recommended to take them orally approximately 30 minutes before meals, as food intake and hyperglycemia may potentially decrease their absorption.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref> Patients should take lower doses of glyburide (&#x02264;10 mg) with breakfast or as soon as the patient consumes the breakfast meal, with higher daily doses (&#x0003e;10 mg) usually divided between breakfast and evening meals.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref></p>
        <p><bold>Renal dosing:</bold> CrCl &#x0003c;60; avoid use. Avoid use in patients on dialysis.</p>
        <p><bold>Hepatic dosing:</bold> Start dosing at 1.25 mg in patients with hepatic impairment.</p>
        <p><bold>Pregnancy:</bold> Multiple studies have&#x000a0;examined&#x000a0;glyburide use in pregnant patients with gestational diabetes. Although the FDA considers glyburide a Category C drug, expert bodies have&#x000a0;started to introduce introducing glyburide as a possible alternative to insulin for antidiabetic therapy.&#x000a0;Glyburide crosses the placenta in utero and&#x000a0;is metabolized by placental microsomes, exposing the fetus to the medication.&#x000a0;</p>
        <p><bold>Lactation:</bold> Concerning lactation, both glyburide and its second-generation counterpart, glipizide, are compatible with breastfeeding as they do not transfer into breast milk or pose no known risk of harm to breastfed infants.<xref ref-type="bibr" rid="article-22328.r7">[7]</xref></p>
      </sec>
      <sec id="article-22328.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Drug Reactions</bold>
</p>
        <p>Hypoglycemia and weight gain are the most frequently encountered&#x000a0;adverse effects of glyburide. Although glyburide is one of the most popular sulfonylureas prescribed, a systematic review conducted by the ADA&#x000a0;found evidence&#x000a0;suggesting that glyburide correlates with a significantly higher risk of hypoglycemic episodes than other insulin secretagogues sulfonylureas by 80% and 44%, respectively.<xref ref-type="bibr" rid="article-22328.r10">[10]</xref>&#x000a0;However, these episodes are most often seen with higher initial glyburide dosing and in patients recently diagnosed, especially&#x000a0;those 65 years and older.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref>&#x000a0;For this reason,&#x000a0;clinicians must consider patient-specific factors and susceptibility to hypoglycemic episodes when considering&#x000a0;a glyburide prescription for a sulfonylurea-na&#x000ef;ve patient.&#x000a0;</p>
        <p>Due to the risk of severe prolonged hypoglycemia with long-acting sulfonylureas (and subsequent risk for falls), glyburide is listed on the 2019 American Geriatrics Society Beers Criteria as a potentially inappropriate medication in those aged 65 and older.<xref ref-type="bibr" rid="article-22328.r11">[11]</xref>&#x000a0;</p>
        <p>The ADA&#x000a0;<italic toggle="yes">Standards of Medical Care in Diabetes</italic>&#x000a0;2023 update also considers long-acting sulfonylureas, such as glyburide, as agents to avoid in older adults due to the risk of hypoglycemia and advises against the drug's use in this population. Treatment with glyburide in this at-risk patient population, especially those with more advanced age and complex medical conditions, is considered "overtreatment" per the ADA. Therefore, treatment de-intensification should be considered via dose reduction, discontinuation, or utilization of lower-risk agents, as long as&#x000a0;individualized glycemic targets are continually achieved.<xref ref-type="bibr" rid="article-22328.r12">[12]</xref></p>
        <p>Possible weight gain can also be a distressing&#x000a0;adverse effect for patients taking glyburide, as with all sulfonylureas. According to the ADA's systematic review, glyburide is less significantly associated with weight gain than other insulin secretagogues. However, if weight gain does occur, coadministration with metformin, a weight-neutral biguanide agent, can be considered to address this issue.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref><xref ref-type="bibr" rid="article-22328.r10">[10]</xref></p>
        <p>A cohort study on patients with type 2 diabetes compared all-cause and cardiovascular mortality for patients on either glyburide or metformin for blood glucose management.<xref ref-type="bibr" rid="article-22328.r13">[13]</xref>&#x000a0;The study found that glyburide monotherapy, compared to metformin, was associated with higher percentages of all-cause (6.3% and 1.6%, respectively) and cardiovascular (4.1% and 0.4%, respectively) deaths, in addition to increases in plasma creatinine.&#x000a0;Other nationwide studies, retrospective cohort studies, and other recent studies have confirmed metformin as having lower all-cause mortality rates and higher survival rates than glyburide and other drugs of its class.<xref ref-type="bibr" rid="article-22328.r13">[13]</xref>&#x000a0;</p>
        <p>Adverse effects that are less likely to occur with glyburide and other sulfonylureas include skin rashes, nausea, and sensitivity to light on rare occasions.<xref ref-type="bibr" rid="article-22328.r9">[9]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Concurrent use of glyburide with bosentan is contraindicated.</p>
        <p>Monitoring for potentially harmful drug-drug interactions is crucial when patients&#x000a0;receive concurrent therapy with salicylates, sulfonamides, drugs containing fibric acid, and warfarin.<xref ref-type="bibr" rid="article-22328.r9">[9]</xref>&#x000a0;Additional medications that may inhibit or induce CYP2C9 include azole antifungals, carbamazepine, phenobarbital, rifampin, St. Johns wort, and dexamethasone. The most beneficial way to mitigate&#x000a0;sulfonylurea and glyburide toxicity is to elevate&#x000a0;the patient's blood glucose level back to its normalized range, depending on the setting.<xref ref-type="bibr" rid="article-22328.r13">[13]</xref></p>
      </sec>
      <sec id="article-22328.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Glyburide has no&#x000a0;boxed&#x000a0;warnings.</p>
        <p>
<bold>Contraindications</bold>
</p>
        <p>Glyburide therapy should not be re-initiated if the patient has a history of allergic reaction to the medication. However, patients with previous allergic reactions to drugs of the same class may not necessarily react to glyburide.<xref ref-type="bibr" rid="article-22328.r1">[1]</xref></p>
        <p>Also,&#x000a0;prescribers must use caution with glyburide in hospitalized patients, who are malnourished, misuse alcohol, have renal and cardiac dysfunctions, or with gastrointestinal disease.<xref ref-type="bibr" rid="article-22328.r9">[9]</xref></p>
      </sec>
      <sec id="article-22328.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>As glyburide rates for hypoglycemia can be higher than other oral antidiabetic agents, close monitoring for signs and symptoms of declining blood glucose levels is required. Hypoglycemia can be life-threatening, and it is crucial to take proper measures if&#x000a0;the condition occurs in any patient.&#x000a0;Monitoring glyburide is also necessary for patients in circumstances that provoke the onset of hypoglycemia, including exercise, lack of eating, and accidental overdosage.<xref ref-type="bibr" rid="article-22328.r9">[9]</xref>&#x000a0;</p>
        <p>To ensure patient safety, it is crucial to be aware of the signs and symptoms of hypoglycemia when initiating glyburide therapy. Patients should be educated on self-monitoring of blood glucose levels and adhere to regularly scheduled blood glucose and HbA1C testing as the ADA recommends.</p>
        <p>Glyburide and other sulfonylureas may also cause liver dysfunction, potentially resulting in cholestatic jaundice, hepatitis, and liver failure, although this is rare.<xref ref-type="bibr" rid="article-22328.r9">[9]</xref>&#x000a0;In patients with liver dysfunction, monitoring of liver function tests may be necessary.</p>
      </sec>
      <sec id="article-22328.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Glyburide toxicity is primarily associated with the risk of severe hypoglycemia due to an excessive dosage, whether it occurs accidentally or intentionally.<xref ref-type="bibr" rid="article-22328.r9">[9]</xref><xref ref-type="bibr" rid="article-22328.r13">[13]</xref>&#x000a0;Due to duplicate metabolism&#x000a0;involving the CYP2C9 enzyme, drug-drug interactions&#x000a0;between&#x000a0;glyburide and other sulfonylureas can also potentiate hypoglycemia.<xref ref-type="bibr" rid="article-22328.r13">[13]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22328.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The interprofessional healthcare team, including clinicians&#x000a0;and pharmacists, must work together to ensure that the best possible treatment outcomes occur in patients with type 2 diabetes. Consistent monitoring of blood glucose and HbA1C levels is vital in determining treatment success with glyburide. Interprofessional healthcare providers&#x000a0;play a crucial role in recognizing the signs and symptoms of hypoglycemia and the frequency of hypoglycemic events while the patient is on glyburide.</p>
        <p>Strong&#x000a0;clinician judgment&#x000a0;is necessary at the first signs of hypoglycemia to determine the appropriateness of continuing therapy. If&#x000a0;patients with type 2 diabetes are not at their goal HbA1C or blood glucose target levels, glyburide dosages may be increased every 2 to 4 weeks until meeting the desired objective.<xref ref-type="bibr" rid="article-22328.r9">[9]</xref>&#x000a0;After initiating glyburide, starting at a low dosage would be considered the safest precaution to mitigate the risk of hypoglycemia and possible weight gain.<bold>
</bold></p>
        <p>Nursing plays a crucial role in glyburide therapy management by reporting potential hypoglycemia and educating patients about its signs, which should be promptly communicated to the rest of the healthcare team. Simultaneously, the pharmacist, nurse practitioner, and primary care provider should educate the patient about the importance of positive lifestyle modifications, including smoking cessation, adopting a healthy diet, participating in an exercise program, and maintaining healthy body weight, as ample evidence supports the benefits of lower body weight in achieving better diabetes control.<xref ref-type="bibr" rid="article-22328.r14">[14]</xref> [Level 5]</p>
        <p>Pharmacists play a critical role in glyburide therapy by verifying appropriate dosing, conducting medication reconciliation, and identifying significant drug-drug interactions, which should be communicated to the rest of the healthcare team for comprehensive patient care.</p>
        <p>In summary, the effective use of glyburide therapy for glycemic control in patients with type 2 diabetes necessitates an interprofessional team approach involving physicians, specialists, specialty-trained nurses, and pharmacists. This collaborative effort, characterized by open communication and shared decision-making, is essential to achieve optimal patient outcomes and ensure the success of glyburide treatment. [Level 5]</p>
      </sec>
      <sec id="article-22328.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22328&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22328">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22328/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22328">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22328.s11">
        <title>References</title>
        <ref id="article-22328.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <article-title>Glibenclamide: a review.</article-title>
            <source>Drugs</source>
            <year>1971</year>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-40</page-range>
            <pub-id pub-id-type="pmid">5004340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Seley</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S140</fpage>
            <page-range>S140-S157</page-range>
            <pub-id pub-id-type="pmid">36507650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouazza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Djerada</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gozalo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Busiah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beltrand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berdugo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Urien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Treluyer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Polak</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>11</issue>
            <fpage>1373</fpage>
            <page-range>1373-1379</page-range>
            <pub-id pub-id-type="pmid">27561267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beltrand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baptiste</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Busiah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bouazza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Godot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boucheron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Djerada</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gozalo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berdugo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tr&#x000e9;luyer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Elie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Polak</surname>
                <given-names>M</given-names>
              </name>
              <collab>GLID-KIR study group</collab>
            </person-group>
            <article-title>Glibenclamide oral suspension: Suitable and effective in patients with neonatal diabetes.</article-title>
            <source>Pediatr Diabetes</source>
            <year>2019</year>
            <month>May</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-254</page-range>
            <pub-id pub-id-type="pmid">30684309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsarenko</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Dzyadz'ko</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rybalko</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>[Glibenclamide as a promising agent for prevention and treatment of cerebral edema].</article-title>
            <source>Zh Vopr Neirokhir Im N N Burdenko</source>
            <year>2017</year>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>88</fpage>
            <page-range>88-93</page-range>
            <pub-id pub-id-type="pmid">28665392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qureshi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gammoh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shakil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Update on Management of Type 2 Diabetes for Cardiologists.</article-title>
            <source>Methodist Debakey Cardiovasc J</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>273</fpage>
            <page-range>273-280</page-range>
            <pub-id pub-id-type="pmid">30788013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kimber-Trojnar</surname>
                <given-names>&#x0017b;</given-names>
              </name>
              <name>
                <surname>Marciniak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patro-Malysza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Skorzynska-Dziduszko</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Poniedzialek-Czajkowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mierzynski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Galczynski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trojnar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leszczynska-Gorzelak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oleszczuk</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Is glyburide safe in pregnancy?</article-title>
            <source>Curr Pharm Biotechnol</source>
            <year>2014</year>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>100</fpage>
            <page-range>100-12</page-range>
            <pub-id pub-id-type="pmid">24720590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quianzon</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Cheikh</surname>
                <given-names>IE</given-names>
              </name>
            </person-group>
            <article-title>History of current non-insulin medications for diabetes mellitus.</article-title>
            <source>J Community Hosp Intern Med Perspect</source>
            <year>2012</year>
            <volume>2</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">23882374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schianca</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Maffioli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bigliocca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corlian&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fra</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Bartoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Derosa</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Sulfonylureas and their use in clinical practice.</article-title>
            <source>Arch Med Sci</source>
            <year>2015</year>
            <month>Aug</month>
            <day>12</day>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>840</fpage>
            <page-range>840-8</page-range>
            <pub-id pub-id-type="pmid">26322096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gangji</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cukierman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gerstein</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Clase</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.</article-title>
            <source>Diabetes Care</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>389</fpage>
            <page-range>389-94</page-range>
            <pub-id pub-id-type="pmid">17259518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Jeffrie Seley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>13. Older Adults: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S216</fpage>
            <page-range>S216-S229</page-range>
            <pub-id pub-id-type="pmid">36507638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raee</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Nargesi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Heidari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mansournia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Larry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabizadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zarifkar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esteghamati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakhjavani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus.</article-title>
            <source>Arch Iran Med</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>141</fpage>
            <page-range>141-146</page-range>
            <pub-id pub-id-type="pmid">28287807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22328.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magkos</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Metabolically healthy obesity: what's in a name?</article-title>
            <source>Am J Clin Nutr</source>
            <year>2019</year>
            <month>Sep</month>
            <day>01</day>
            <volume>110</volume>
            <issue>3</issue>
            <fpage>533</fpage>
            <page-range>533-539</page-range>
            <pub-id pub-id-type="pmid">31240297</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
